CEL 4000
Alternative Names: CEL-4000; DerG-PG70 vaccine - CEL-SCI CorporationLatest Information Update: 26 Mar 2024
At a glance
- Originator CEL-SCI Corporation
- Class Antirheumatics; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Immunomodulators; Regulatory T-lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 19 Mar 2024 CEL 4000 is still in preclinical development in Rheumatoid-arthritis in USA (Parenteral) (CEL-SCI corporation pipeline March 2024)
- 19 Mar 2024 CEL-SCI corporation plans phase I trial in Rheumatoid arthritis (CEL-SCI corporation pipeline March 2024)
- 28 May 2022 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)